Skip to main content

23.12.2016 | Epidemiology | Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017

The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients

Breast Cancer Research and Treatment > Ausgabe 3/2017
Yun Li, Allison W. Kurian, Irina Bondarenko, Jeremy M. G. Taylor, Reshma Jagsi, Kevin C. Ward, Ann S. Hamilton, Steven J. Katz, Timothy P. Hofer
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10549-016-4086-3) contains supplementary material, which is available to authorized users.
Steven J. Katz and Timothy P. Hofer share senior authorship.



To quantify the influence of RS assay on changing chemotherapy plans in a general practice setting using causal inference methods.


We surveyed 3880 newly diagnosed breast cancer patients in Los Angeles and Georgia in 2013–14. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing.


A half of the 1545 women eligible for testing (ER+ or PR+, HER2−, and stage I–II) received RS. We estimate that 30% (95% confidence interval (CI) 10–49%) of patients would have changed their treatment selections after RS assay, with 10% (CI 0–20%) being encouraged to undergo chemotherapy and 20% (CI 10–30%) being discouraged from chemotherapy. The subgroups whose treatment selections would be changed the most by RS were patients with positive nodes (44%; CI 24–64%), larger tumor (43% for tumor size >2 cm; CI 23–62%), or younger age (41% for <50 years, CI 23–58%). The assay was associated with a net reduction in chemotherapy use by 10% (CI 4–16%). The reduction was much greater for women with positive nodes (31%; CI 21–41%), larger tumor (30% for tumor size >2 cm; CI 22–38%), or younger age (22% for <50 years; CI 9–35%).


RS substantially changed chemotherapy treatment selections with the largest influence among patients with less favorable pre-test prognosis. Whether this is optimal awaits the results of clinical trials addressing the utility of RS testing in selected subgroups.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Online Appendix (DOCX 19 kb)
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe
  1. Sie können e.Med Gynäkologie & Urologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.